Home World News FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection World News FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 431 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Vulnerability in Brain Tumors May Open Door to New Treatments September 26, 2022 Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... June 7, 2022 Neratinib Plus Capecitabine Outperforms Lapatinib Plus Capecitabine in Asian Patients with... November 21, 2020 Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence... July 6, 2026 Load more HOT NEWS FDA Approvals Expand Initial Treatment Options for Multiple Myeloma Embedding research integrity at the core of our science FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful...
